VivoSeq
Neurology

CIDP

2

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

CIDP is an early-stage landscape with 2 programs across 1 company. The most active players are Grifols Therapeutics LLC. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

GAMUNEX-C

Grifols Therapeutics LLC

Xembify

Grifols Therapeutics LLC

Approved
No programs

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Completed3 · 43%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
Recruiting·UUniversity of Aarhus·Phase 4·NCT04589299·60 enrolled
IVIG vs SCIG in CIDP
Recruiting·RRutgers, The State University of New Jersey·Phase 1·NCT05584631·20 enrolled
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Recruiting·Grifols Therapeutics LLC logoGrifols Therapeutics LLC·Phase 3·NCT07540221·40 enrolled
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Completed·BBaxalta now part of Shire·Phase 3·NCT02955355·85 enrolled
Interest of Mycophenolate for CIDP Weaning
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02494505·40 enrolled
Immunoglobulin Dosage and Administration Form in CIDP and MMN
Completed·—·N/A·NCT02111590·36 enrolled
Transcriptome Analysis of the Peripheral Blood in CIDP
Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02404298·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)